Quantcast
Last updated on April 18, 2014 at 10:00 EDT

Latest Auxilium Pharmaceuticals Inc. Stories

2013-10-07 16:25:31

- Clinical Papers Presented on Four-Year Data from CORDLESS Recurrence Study and Three-Year Safety Data - LYNBROOK, N.Y., Oct. 7, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) in the U.S. and XIAPEX(®) in the EU, announced today that data from multiple trials evaluating the use of XIAFLEX ("collagenase clostridium histolyticum" or "CCH") in adult patients...

2013-10-07 08:24:58

-42 Percent of Joints Previously Treated Successfully with XIAFLEX Exhibited Disease Recurrence at Year 4- CHESTERBROOK, Pa., Oct. 7, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced results from Year 4 of the Collagenase Optimal Reduction of Dupuytren's - Long-term Evaluation of Success Study ("CORDLESS"). These data indicated that the overall recurrence rate at Year 4 was 42.1 percent for patients previously treated...

2013-10-03 08:29:38

- Four-Year Data from CORDLESS Recurrence Study and Three-Year Safety Data to be Presented as Clinical Papers - CHESTERBROOK, Pa., Oct. 3, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that data from multiple trials evaluating the use of XIAFLEX ("collagenase clostridium histolyticum" or "CCH") in adult patients with Dupuytren's contracture with a palpable cord will be presented at the upcoming 68(th) Annual Meeting...

2013-09-20 08:25:00

CHESTERBROOK, Pa., Sept. 20, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, today announced it entered into an Incremental Assumption Agreement ("Incremental Agreement") with Morgan Stanley Senior Funding, Inc. ("MSSF") under its existing Credit Agreement with MSSF. Under the Incremental Agreement, the Company raised an additional $50,000,000 from a syndicate of lenders, and this additional amount is on terms consistent with...

2013-09-05 08:29:25

CHESTERBROOK, Pa., Sept. 5, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that executive management will participate in the Stifel Nicolaus Healthcare Conference to be held September 11-12, 2013 at the Four Seasons Hotel in Boston. Mr. Jim Fickenscher, Chief Financial Officer, is scheduled to present an overview of the Company and its product pipeline at 8:00 a.m. ET on Thursday, September 12, 2013. (Logo:...

2013-09-03 12:26:23

CHESTERBROOK, Pa., Sept. 3, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that executive management will participate in the Morgan Stanley Global Healthcare Conference to be held September 9-11, 2013 at the Grand Hyatt Hotel in New York. Mr. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product pipeline at 10:35 a.m. ET on Monday, September 9, 2013. (Logo:...

2013-08-28 08:25:43

CHESTERBROOK, Pa., Aug. 28, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration ("FDA") has notified the Company that it is extending the Prescription Drug User Fee Act ("PDUFA") goal date for the Company's supplemental biologics license application ("sBLA") for XIAFLEX(® )(collagenase clostridium histolyticum) for the treatment of Peyronie's disease ("PD") from September...

2013-08-08 08:31:39

CHESTERBROOK, Pa., Aug. 8, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that executive management will participate in the Canaccord Genuity Growth Conference to be held August 14-15, 2013 at the Intercontinental Boston Hotel. Mr. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product pipeline at 3:30 p.m. ET on Thursday, August 15, 2013. (Logo:...

2013-08-08 08:29:40

LYNBROOK, N.Y., Aug. 8, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first-in-class collagenase-based products marketed as XIAFLEX(® )in the U.S. and XIAPEX(®)( )in the EU, today reported its financial results for the second quarter ended June 30, 2013 and provided a corporate update. "We continue to make steady progress in the clinical development and commercial growth of XIAFLEX. We are anticipating a major landmark related...

2013-08-01 08:33:36

- 2Q13 Total Net Revenues Increased by 29% vs. 2Q12 to $100.5 MM - CHESTERBROOK, Pa., Aug. 1, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, today announced financial results for the quarter ending on June 30, 2013. The Company also highlighted select commercial, regulatory and clinical development progress in the second quarter of 2013 and has updated its previously announced financial guidance for 2013. (Logo:...